2016至2019年西班牙呼吸道合胞病毒感染住院儿童的经济负担
这项回顾性观察研究量化了2016至2019年西班牙国家医疗系统收治的18岁以下呼吸道合胞病毒(RSV)住院儿童的医疗费用,并与未明确病原的细支气管炎/支气管炎/肺炎(UBP)及流感费用对比。西班牙免疫规划目前仅推荐6至59月龄接种流感疫苗、6月龄以下使用RSV单克隆抗体,而37%的RSV住院患者年龄≥6月龄。
要点
- 2016至2019年RSV住院41934例、UBP住院70160例、流感住院8525例,RSV与UBP、流感住院发病率均以6月龄以下婴儿最高。
- 6月龄以下至少一项危险因素的RSV病例单次住院平均费用最高,高危4760欧元 vs 低危2827欧元。
核心结论
- 与流感相比,RSV的经济负担显著更高;西班牙免疫规划推荐6至59月龄接种流感疫苗、6月龄以下使用RSV单克隆抗体,RSV免疫接种在年长儿童中仍有待实施,因37%的RSV住院患者年龄≥6月龄。
研究设计与样本
- 回顾性观察研究,纳入2016至2019年西班牙国家医疗系统收治的18岁以下RSV住院儿童,并与UBP及流感住院儿童的费用进行对比。
- 共纳入RSV住院儿童41934例、UBP住院儿童70160例、流感住院儿童8525例。
- 按年龄组、危险类别和早产状态报告每次住院的平均费用,并根据人群发病率和每次住院平均费用计算年度总住院费用。
主要发现
- RSV、UBP和流感住院发病率均以6月龄以下婴儿最高。
- 6月龄以下至少一项危险因素的RSV病例单次住院平均费用最高,高危4760欧元 vs 低危2827欧元。
- 其他年龄组高危儿童单次住院平均费用为3704至4352欧元,低危儿童为2687至3475欧元,早产儿为4300至44594欧元。
- 0至5月龄组中,UBP单次住院平均费用高危4189欧元、低危2666欧元,流感高危3134欧元、低危2081欧元,RSV与流感合并感染高危4809欧元、低危2887欧元。
关键数值与推荐
- 西班牙免疫规划推荐6至59月龄接种流感疫苗,RSV单克隆抗体仅推荐用于6月龄以下儿童。
- 37%的RSV住院患者年龄≥6月龄。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This retrospective observational study aimed to quantify the costs associated with hospitalized respiratory syncytial virus (RSV) in children <18 years admitted to the Spanish National Healthcare System between 2016 and 2019 and contrast them with the costs of unspecified bronchiolitis/bronchitis/pneumonia (UBP) and influenza. The mean cost per hospitalization episode was reported by age group, risk category and prematurity. Total annual hospitalization costs were calculated from population incidence rates and the mean cost per episode. A total of 41,934 children were hospitalized with RSV, 70,160 with UBP and 8525 with influenza during 2016-2019. The highest incidence of hospitalization for RSV, UBP, and influenza occurred among infants <6 months. The mean cost per episode was highest for RSV cases aged <6 months with at least one risk factor (€4760 high vs €2827 low risk), while the mean cost ranged from €3704-4352 for high-risk and €2687-3475 for low-risk children of other ages, and from €4300-44,594 for preterm infants. In the 0-5 months age group, the mean cost per episode for UBP was €4189 and €2666 for high and low risk, and for influenza it was €3134 and €2081, respectively; while the mean cost of co-infected RSV-influenza cases was €4809 and €2887, respectively. The mean total annual estimated cost for RSV for children aged 0-17 years was €39.3 M based only on reported cases, rising to €53.8 M if we correct for under-diagnosis and all RSV-attributable cases are considered. In contrast, the mean total annual cost for influenza was €5.9 M. Compared to influenza, RSV has a substantially higher economic burden; nevertheless, the Spanish immunization schedule recommends influenza vaccine between 6 and 59 months of age and RSV monoclonal antibody only for those aged <6 months. RSV immunization is still to be implemented in older children, considering that 37 % of RSV hospitalized patients were aged ≥6 months.
引用
- Haeberer M, López-Ibáñez de Aldecoa A, Seabroke S, et al. Economic burden of children hospitalized with respiratory syncytial virus infection in Spain, 2016-2019. Vaccine. 2024. PMID: 39515196. doi:10.1016/j.vaccine.2024.126512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。